Equities researchers at Stephens initiated coverage on shares of Delcath Systems (NASDAQ:DCTH - Get Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm set an "overweight" rating and a $25.00 price target on the stock. Stephens' target price would indicate a potential upside of 253.61% from the stock's previous close.
Other analysts have also recently issued research reports about the stock. HC Wainwright boosted their price objective on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, March 27th. StockNews.com raised Delcath Systems to a "sell" rating in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $19.80.
View Our Latest Stock Analysis on Delcath Systems
Delcath Systems Stock Up 30.9 %
Shares of DCTH traded up $1.67 during midday trading on Tuesday, hitting $7.07. The company's stock had a trading volume of 1,586,983 shares, compared to its average volume of 237,275. Delcath Systems has a one year low of $2.25 and a one year high of $7.99. The stock has a market capitalization of $196.40 million, a price-to-earnings ratio of -2.38 and a beta of 0.55. The company's fifty day simple moving average is $4.89 and its two-hundred day simple moving average is $4.15.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.19. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. The business had revenue of $0.54 million during the quarter, compared to analysts' expectations of $0.48 million. During the same period in the prior year, the company earned ($0.86) EPS. On average, research analysts predict that Delcath Systems will post -1.45 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Gil Aharon bought 26,882 shares of the company's stock in a transaction dated Tuesday, March 19th. The stock was purchased at an average cost of $3.72 per share, with a total value of $100,001.04. Following the transaction, the director now owns 1,069,710 shares in the company, valued at approximately $3,979,321.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 17.94% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Delcath Systems
A number of institutional investors and hedge funds have recently made changes to their positions in DCTH. Levin Capital Strategies L.P. purchased a new stake in Delcath Systems during the third quarter valued at $162,000. Vivo Capital LLC lifted its stake in shares of Delcath Systems by 57.4% during the third quarter. Vivo Capital LLC now owns 1,855,191 shares of the company's stock worth $7,514,000 after buying an additional 676,404 shares during the period. Stonepine Capital Management LLC raised its holdings in shares of Delcath Systems by 81.2% during the third quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company's stock worth $2,779,000 after purchasing an additional 307,453 shares during the last quarter. Armistice Capital LLC acquired a new position in shares of Delcath Systems in the 3rd quarter valued at $664,000. Finally, WealthPlan Investment Management LLC purchased a new position in shares of Delcath Systems during the 4th quarter valued at approximately $73,000. Hedge funds and other institutional investors own 61.12% of the company's stock.
About Delcath Systems
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
See Also
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
